The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management characterized fiscal 2026 as a foundational year focused on streamlining the organization, reducing cost structures, and improving accountability through a formal transformation plan.

Performance was significantly impacted by geopolitical tensions and tariff uncertainty in China, which accounted for approximately $58 million of the total product revenue decline.

The company is pivoting to a 'partner-centric' model, utilizing nonbinding letters of intent with Samsung Medison and Research Laboratories to accelerate innovation in imaging and AI without internal capital intensity.

Service revenue growth of 6% in Q4 was driven by strategic contract pricing actions and an expanding global installed base, serving as a stabilizing factor against volatile product sales.

Management highlighted that clinical data presented at ESTRO 26 for CyberKnife and Radixact platforms is driving a shift toward ultra-hypofractionated and adaptive radiotherapy, which they believe validates their technology roadmap.

Operational discipline led to $20 million in realized cost and margin improvements during the year, exceeding the initial target of $12 million.

Management is not providing formal revenue or adjusted EBITDA guidance for fiscal 2027 due to persistent geopolitical uncertainty, trade policy volatility, and long sales cycles.

The company expects approximately $15 million of incremental annualized cost and margin improvements in fiscal 2027, though the final contribution depends on product demand levels.

Strategic focus for 'Transformation Phase 2' centers on expanding market reach through improved distributor performance and driving service margin expansion via remote diagnostics and price optimization.

The financial framework for the coming year assumes a 'covenant holiday' through December 2027, providing a runway to invest in commercial execution without immediate debt-related constraints.

Management plans to implement a reverse stock split, subject to shareholder approval, to improve the company's capital structure and market positioning.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

A comprehensive transaction with TCW Asset Management includes converting $40 million of debt into preferred equity at a 105% premium to the pre-announcement share price.

Q4 gross margins were impacted by a $5.8 million one-time benefit from the invalidation of IEPA tariffs, partially offset by a $1.5 million non-recurring write-down of obsolete inventory.

The company recognized $16.2 million in non-recurring restructuring expenses for the full year, covering severance and transformation costs, which are now expected to be substantially complete.

Liquidity was bolstered by a $15 million cash investment from TCW and the full draw of an $18 million delayed draw facility used to retire maturing convertible notes.